US Federal House Bill HB7877

US Federal 2025-2026 Regular Session

• Introduced: 3/9/26
• Refer: 3/9/26

Caption

Shane DiGiovanna Act

Impact

This legislation is poised to impact state Medicaid programs significantly, mandating that certain wound care treatments become covered items under state plans. The demonstration program will operate nationwide, providing a structured approach to evaluating how effectively these treatments can improve health outcomes for patients with epidermolysis bullosa. By necessitating this coverage, the bill aims to alleviate the financial burden of wound care on affected families, ultimately promoting better overall health for these individuals.

Summary

House Bill 7877, titled the Shane DiGiovanna Act, aims to establish a demonstration program requiring the Secretary of Health and Human Services to test the mandatory coverage of wound care treatment for individuals with epidermolysis bullosa under the Medicaid program. The proposed program signifies a progressive step towards ensuring specific medical needs are adequately covered by Medicaid, particularly for a condition that involves severe skin fragility and requires comprehensive wound care management. By including various necessary wound care supplies and medications as eligible treatments, the bill addresses critical healthcare access issues faced by individuals with this rare condition.

Contention

While the bill presents a necessary advancement in healthcare coverage, potential points of contention may arise around the funding and implementation of this demonstration program. Critics may question the fiscal implications for state Medicaid budgets and whether this legislation sets a precedent for expanding coverage for other conditions. Additionally, the evaluation phase at the conclusion of the two-year program will need to provide solid evidence of effectiveness to garner ongoing legislative support and funding for broader adoption of such treatment mandates.